Use of Bevacizumab Beyond Disease Progression in Platinum-Resistant Ovarian Cancer
Posted: Wednesday, October 28, 2020
A recent study from researchers at multiple Japanese institutions, led by Toru Sugiyama, MD, PhD, of St. Mary’s Hospital, showed improved progression-free survival in patients with platinum-resistant ovarian cancer who received bevacizumab treatment beyond disease progression. The results of this open-label, randomized, phase II trial were presented during a plenary session of the 2020 International Gynecologic Cancer Society (IGCS) Annual Global Meeting (Abstract 1271).
Patients aged 20 years and older with fallopian tube, epithelial ovarian, or primary peritoneal carcinoma were eligible for the trial. Further criteria included histologic confirmation and disease progression after 6 months of at least three platinum-based chemotherapy cycles. Patients were randomly assigned equally to one of two groups: group A received single-agent chemotherapy, and group B received a combination of single-agent chemotherapy and bevacizumab.
A total of 103 patients were enrolled in the study: 51 in group A and 52 in group B. Group B had longer median progression-free survival than group A (4.0 months vs. 3.1 months; hazard ratio = 0.54; one-sided P = .0082). Furthermore, group B also had longer median overall survival (15.3 vs. 11.3 months; hazard ratio = 0.67; two-sided P = .1556) and a better overall response rate (25.0% vs. 13.7%). The safety profile was comparable between the two groups.
Researchers concluded: “These results suggest chemotherapy combined with bevacizumab has efficacy beyond disease progression. A phase III trial is warranted to confirm our findings.”
Disclosure: No disclosure information was provided.
